Pfizer Deepens Investment in CytoReason for Novel Drug Discovery and Development

Following a three-year collaboration that kicked off when Pfizer embraced its biological models for new immune-mediated disease and cancer immunotherapy drug development, AI-powered drug discovery company CytoReason and its long-term biopharma powerhouse partner are inking a new, wide-ranging deal...